Loading
A phase 3 trial of Thermal ablation in Hepatocellular carcinoma, run by Chinese PLA General Hospital, with a status the registry has not verified recently.
Thermal Ablation Combined With Anlotinib and TQB2450 Solution for HCC is a phase 3 interventional study registered as NCT04665609 by Chinese PLA General Hospital, with 80 participants planned, started 2021-03-05 and due to reach its primary completion in 2022-12-31. Interventions recorded: Anlotinib and TQB2450 solution, TQB2450 solution. Conditions recorded: Hepatocellular Carcinoma, Thermal Ablation, Anlotinib, PDL-1.
Linked to the technology Thermal ablation because the registry's title names it ("thermal ablation") and Hepatocellular carcinoma among its conditions. Registry record only: no result has been read by an editor.
Shares Thermal ablation (RFA, microwave, cryo) and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.